Jules Bordet Institute

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Private

Established: 1939-01-01

Employees: 1K

Market Cap: -

Website: http://www.bordet.be

Clinical Trials

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

Phase 2

Active, not recruiting

Conditions: HER-2 Positive Breast Cancer

Interventions: Drug: T-DM1
Procedure: 89Zr-trastuzumab

First Posted Date: 2012-03-28

Last Posted Date: 2023-08-14

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 90

Registration Number: NCT01565200

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇳🇱
Vrije Universiteit Amsterdam (VUMC), Amsterdam, Netherlands
🇧🇪
Universitair Ziekenhuis Antwerpen (UZA), Antwerpen, Edegem, Belgium

and more 2 locations

Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Other: cardiac MRI

First Posted Date: 2012-03-15

Last Posted Date: 2013-08-30

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 73

Registration Number: NCT01554943

Locations: 🇧🇪
Jules Bordet Institute, Brussels, Belgium

Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: EndoTAG-1

First Posted Date: 2012-02-23

Last Posted Date: 2013-06-17

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 18

Registration Number: NCT01537536

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia

Phase 1

Conditions: Acute Myelogenous Leukemia
Myeloid Leukemia in Remission
Effects of Immunotherapy

Interventions: Biological: Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)

First Posted Date: 2012-01-20

Last Posted Date: 2012-01-20

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 20

Registration Number: NCT01513109

Locations: 🇧🇪
Institut Jules Bordet, tumor center of the Universite Libre de Bruxelles, Brussels, Belgium

A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma

Phase 2

Completed

Conditions: Ovarian Carcinoma
Relapse

Interventions: Drug: oxaliplatin

First Posted Date: 2011-11-29

Last Posted Date: 2014-10-15

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 90

Registration Number: NCT01481701

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients

Phase 1

Completed

Conditions: Breast Neoplasms
Secondary
HER2 Positive Carcinoma of Breast

Interventions: Drug: Zr89-trastuzumab

First Posted Date: 2011-08-19

Last Posted Date: 2017-04-18

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 20

Registration Number: NCT01420146

Locations: 🇧🇪
Jules Bordet Institut, Brussels, Belgium

Early Cardiac Toxicity of Adjuvant CT in Elderly BC.

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: epirubicin, cyclophosphamide, docetaxel

First Posted Date: 2011-02-23

Last Posted Date: 2013-08-30

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 2

Registration Number: NCT01301040

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: chemotherapy

First Posted Date: 2011-02-07

Last Posted Date: 2016-02-24

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 97

Registration Number: NCT01290926

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
Hopitaux St Joseph, Liege, Belgium
🇧🇪
Universiteit Ziekenhuis Antwerpen, Antwerpen, Belgium

and more 4 locations

Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer

Not Applicable

Completed

Conditions: Colon Cancer

Interventions: Drug: FOLFOX

First Posted Date: 2009-10-14

Last Posted Date: 2023-08-07

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 235

Registration Number: NCT00994864

Locations: 🇧🇪
Clin Université St-Luc Bruxelles, Brussels, Belgium
🇧🇪
Hôpital Erasme, Brussels, Belgium
🇧🇪
CHU De Liège, Liège, Belgium

and more 18 locations

PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.

Completed

Conditions: Colorectal Cancer Metastatic
Early Response Evaluation
Fdg-PET

Interventions: Procedure: FDG-PET imaging

First Posted Date: 2008-08-26

Last Posted Date: 2011-02-24

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 40

Registration Number: NCT00741481

Locations: 🇧🇪
Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy